课题基金 / 基金详情

Cincinnati Neuro-Oncology Research Core

Cincinnati Neuro-Oncology Research Core
辛辛那提神经肿瘤学研究核心
批准号:
7944174
负责人:
NANCY RATNER
金额:
$71.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-08-31

项目摘要

项目成果

NANCY RATNER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Provided by the applicant): Tumors of the nervous system are the second most common types of neoplasm in the pediatric population. In contrast to the most common cancer (leukemia), strides have been made in improving outcomes for some nervous system tumors but many remain difficult or impossible to treat effectively. There is opportunity to dramatically improve outcome for nervous system cancer in children through development of new therapies. It is our hypothesis that interactive programs based in developmental biology studying individual nervous system tumor types will identify critical differences and similarities in molecular processes and extend the applicability of new therapies. Animal models and neural stem/progenitor cell models systems are now being used to study nervous system cancers and for preclinical development of novel therapies for nervous system tumors. Whole genome approaches are adding insight into developmental regulation and carcinogenesis. The goal of this proposal is to contribute to development of a multi-disciplinary, world-class Neuro-Oncology focus group within the Cincinnati Children's Hospital aimed at attacking the problem of neural tumors. Taking advantage of our institutional strengths in developmental biology and informatics, this will be accomplished by recruitment of 2 new Tenure Track faculty members. One is a developmental biologist with interest in the hippo signaling pathway and the other a neural tumor focused bioinformatician.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Identification of novel pathways causing NF1-driven Schwann cell tumors
Identification of novel pathways causing NF1-driven Schwann cell tumors
Targeting Complement 5a-Mediated Immunoregulation for Neurofibroma Therapy
Targeting complement 5a-mediated immunoregulation for neurofibroma therapy
海外基金